[ad_1]
Johnson & Johnson JNJ is set to release earnings results for its first quarter before the opening bell on April 16, 2024.
Analysts expect the New Brunswick, New Jersey-based company to report quarterly earnings at $2.64 per share, up from $2.41 per share in the year-ago period. Johnson & Johnson is projected to report quarterly revenue of $21.40 billion, compared to $24.75 billion in the year-earlier quarter, according to data from Benzinga Pro.
Rallybio recently announced a collaboration with Johnson & Johnson to support the development of complementary therapeutic approaches aimed at reducing the risk of fetal and neonatal alloimmune thrombocytopenia (FNAIT).
Johnson & Johnson shares rose 0.1% to close at $147.59 on Monday.
Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let’s have a look at how Benzinga’s most-accurate analysts have rated the company in the recent period.
- Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating with a price target of $215 on April 15, 2024. This analyst has an accuracy rate of 62%.
- Morgan Stanley analyst Terence Flynn maintained an Equal-Weight rating and cut the price target from $170 to $169 on Jan. 24, 2024. This analyst has an accuracy rate of 69%.
- Raymond James analyst Jayson Bedford maintained an Outperform rating and raised the price target from $172 to $175 on Jan. 3, 2024. This analyst has an accuracy rate of 68%.
- Wells Fargo analyst Larry Biegelsen downgraded the stock from Overweight to Equal-Weight and cut the price target from $170 to $163 on Dec. 13, 2023. This analyst has an accuracy rate of 73%.
- UBS analyst Danielle Antalffy upgraded the stock from Neutral to Buy with a price target of $180 on Dec. 1, 2023. This analyst has an accuracy rate of 62%.
Read This Next: Brightcove And 1 Other Penny Stock Insiders Are Buying
Market News and Data brought to you by Benzinga APIs
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
[ad_2]
Source link